Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-25-036161
Filing Date
2025-04-28
Accepted
2025-04-28 17:05:28
Documents
19
Period of Report
2025-06-13

Document Format Files

Seq Description Document Type Size
1 PROXY STATEMENT ea0237609-03.htm   iXBRL DEF 14A 1336777
6 GRAPHIC tjoshua_sig.jpg GRAPHIC 12690
7 GRAPHIC tpaul-sig.jpg GRAPHIC 8507
8 GRAPHIC tproxy_001.jpg GRAPHIC 1387094
  Complete submission text file 0001213900-25-036161.txt   5399363

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE lgvn-20250428.xsd EX-101.SCH 10477
3 XBRL DEFINITION FILE lgvn-20250428_def.xml EX-101.DEF 3300
4 XBRL LABEL FILE lgvn-20250428_lab.xml EX-101.LAB 35387
5 XBRL PRESENTATION FILE lgvn-20250428_pre.xml EX-101.PRE 6772
21 EXTRACTED XBRL INSTANCE DOCUMENT ea0237609-03_htm.xml XML 119397
Mailing Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136
Business Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136 305-302-7158
Longeveron Inc. (Filer) CIK: 0001721484 (see all company filings)

EIN.: 472174146 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40060 | Film No.: 25881447
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)